Header and Body 2

Problem Addressed

Protein- and peptide-based vaccines, a major class of vaccination strategies, have not been effective against HIV. HIV poses challenges to the generation of prophylactic immune responses because of the antigenic diversity of its viral proteins and its similarity to self-epitopes. Therefore, current vaccination efforts have been limited by either safety or efficacy issues, and the need remains for an effective HIV vaccine. This technology holds potential as a vaccine against HIV and, more broadly, as a method of improving the antigen-induced immune response in vaccination against other diseases.